Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
BioNTech SE ( (BNTX) ) has issued an announcement.
On February 3, 2025, BioNTech SE announced the completion of its acquisition of Biotheus, a clinical-stage biotechnology company dedicated to developing novel antibodies for oncological and inflammatory diseases. This acquisition is a strategic move to bolster BioNTech’s oncology strategy, particularly in developing BNT327, a bispecific antibody targeting advanced cancers. The transaction, valued at $800 million with additional performance-based payments, provides BioNTech full global rights to BNT327 and Biotheus’ entire pipeline, including its in-house antibody generation platform. The acquisition strengthens BioNTech’s capabilities in research, development, and commercialization of cancer therapies and expands its operations with a new research and development hub in China. This move is expected to enhance BioNTech’s position in the biotechnology industry and provide significant growth opportunities in oncology.
More about BioNTech SE
BioNTech SE is a global next-generation immunotherapy company focusing on pioneering novel investigative therapies for cancer and other serious diseases. The company leverages a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals, including individualized mRNA-based therapies, chimeric antigen receptor T cells, protein-based therapeutics, and antibody-drug conjugate therapeutics. BioNTech collaborates with several global and specialized pharmaceutical partners such as Pfizer and Regeneron.
YTD Price Performance: 7.35%
Average Trading Volume: 833,649
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $29.67B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.
